FDA Accepts Vertex's BLA for Povetacicept in IgA Nephropathy with November 2026 PDUFA Date

FDA Accepts Vertex's BLA for Povetacicept in IgA Nephropathy with November 2026 PDUFA Date

On June 1, 2026, Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for povetacicept for accelerated approval in adults with immunoglobulin A nephropathy (IgAN). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026. If approved, the drug will become the first commercialized therapy in Vertex's emerging nephrology franchise.

Povetacicept is an investigational, engineered fusion protein designed as a dual inhibitor of two key cytokines: BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand). These cytokines promote B cell activation, differentiation, and survival, which drive the pathogenesis of IgAN—a progressive, life-threatening autoimmune kidney disease affecting approximately 330,000 people in the US and Europe.

Pivotal Phase 3 RAINIER Trial Results

The BLA submission is supported by a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial, which is the largest clinical trial conducted to date in IgAN (enrolling 605 adult patients):

• Proteinuria Reduction: The trial successfully met its primary objective, with patients treated with an 80 mg subcutaneous dose of povetacicept every four weeks achieving a 52.0% reduction from baseline in their urine protein to creatinine ratio (UPCR) at Week 36. This represents a statistically significant and clinically meaningful 49.8% reduction compared to the placebo group (P < 0.0001).
• Disease Biomarker Reduction: The trial met its first secondary objective, demonstrating a 77.4% reduction from baseline in serum galactose-deficient IgA1 (Gd-IgA1)—the pathological antibody responsible for IgAN kidney damage—compared to a 9.1% increase in the placebo group, representing a net 79.3% reduction over placebo (P < 0.0001).
• Hematuria Resolution: For patients with baseline hematuria (blood in the urine), 85.1% in the povetacicept group achieved resolution by Week 36, compared to just 23.4% in the placebo group (P < 0.0001).

Safety and Administration

Povetacicept was generally safe and well-tolerated, with most adverse events reported as mild to moderate and no serious drug-related adverse events. Upon potential FDA approval, Vertex plans to launch povetacicept as a low-volume (<0.5 mL) subcutaneous autoinjector designed for convenient, once-monthly (every 4 weeks) at-home administration.¹

Vertex is also evaluating povetacicept in other autoimmune kidney diseases, including the Phase 2/3 OLYMPUS trial in primary membranous nephropathy (pMN), and has recently initiated the ETNA Phase 2 trial in generalized myasthenia gravis (gMG).